{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:15:45Z","timestamp":1775682945808,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40801-024-00446-x","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T09:02:11Z","timestamp":1723107731000},"page":"529-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prescribing Cascades of Loop Diuretics and Anti-vertigo Drugs Following Treatment with Gabapentinoids and Benzodiazepines: Prescription Sequence Symmetry Analysis of a Large-Scale Claims Database Including Japanese Older Adults"],"prefix":"10.1007","volume":"11","author":[{"given":"Rina","family":"Omata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Asami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6913-9930","authenticated-orcid":false,"given":"Hisashi","family":"Urushihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"issue":"24","key":"446_CR1","volume":"1","author":"MC Rodrigues","year":"2016","unstructured":"Rodrigues MC, Oliveira C. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. Rev Lat Am Enfermagem. 2016;1(24): e2800.","journal-title":"Rev Lat Am Enfermagem"},{"issue":"4","key":"446_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40266-014-0163-7","volume":"31","author":"L Pasina","year":"2014","unstructured":"Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, et al. Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs Aging. 2014;31(4):283\u20139.","journal-title":"Drugs Aging"},{"issue":"2","key":"446_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.amjopharm.2010.03.005","volume":"8","author":"M Akazawa","year":"2010","unstructured":"Akazawa M, Imai H, Igarashi A, Tsutani K. Potentially inappropriate medication use in elderly Japanese patients. Am J Geriatr Pharmacother. 2010;8(2):146\u201360.","journal-title":"Am J Geriatr Pharmacother"},{"key":"446_CR4","unstructured":"Ministry of Health, Labour and Welfare. Statistics of medical care activities in public health insurance 2021: outline of results: 2. Drug usage [in Japanese]. 2021 2021. Available from: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/sinryo\/tyosa21\/dl\/yakuzai.pdf. Accessed 6 Nov 2023."},{"issue":"1","key":"446_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.","journal-title":"BMC Geriatr"},{"key":"446_CR6","unstructured":"Ministry of Health, Labour and Welfare. Guidelines for proper use of medicines in the elderly: an introduction [in Japanese]. 2018. Available from: https:\/\/www.mhlw.go.jp\/content\/11121000\/kourei-tekisei_web.pdf. Accessed 6 Nov 2023."},{"issue":"7115","key":"446_CR7","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/bmj.315.7115.1096","volume":"315","author":"PA Rochon","year":"1997","unstructured":"Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096\u20139.","journal-title":"BMJ"},{"issue":"10081","key":"446_CR8","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/S0140-6736(17)31188-1","volume":"389","author":"PA Rochon","year":"2017","unstructured":"Rochon PA. The prescribing cascade revisited. Lancet. 2017;389(10081):1778\u201380.","journal-title":"Lancet"},{"issue":"11","key":"446_CR9","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/jgs.15543","volume":"66","author":"H Brath","year":"2018","unstructured":"Brath H, Mehta N, Savage RD, Gill SS, Wu W, Bronskill SE, et al. What is known about preventing, detecting, and reversing prescribing cascades: a scoping review. J Am Geriatr Soc. 2018;66(11):2079\u201385.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"446_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.18773\/austprescr.2011.084","volume":"34","author":"LM Kalisch","year":"2011","unstructured":"Kalisch LM, Caughey GE, Roughead EE, Gilbert AL. The prescribing cascade. Austr Prescr. 2011;34(6):162\u20136.","journal-title":"Austr Prescr."},{"issue":"1","key":"446_CR11","first-page":"21","volume":"4","author":"D Kwan","year":"2014","unstructured":"Kwan D, Farrell B. Polypharmacy: optimizing medication use in elderly patients. CGS J CME. 2014;4(1):21\u20137.","journal-title":"CGS J CME"},{"key":"446_CR12","volume-title":"Hazzard\u2019s geriatric medicine and gerontology","author":"PA Rochon","year":"2017","unstructured":"Rochon PA, Sudeep SG, Gurwitz JH, et al. General principles of pharmacology and appropriate prescribing. In: Halter JB, Ouslander JG, Studenski S, High KP, Asthana S, Supiano MA, et al., editors. Hazzard\u2019s geriatric medicine and gerontology. 7th ed. New York: McGraw Hill; 2017.","edition":"7"},{"key":"446_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.archger.2017.12.010","volume":"77","author":"Y Suzuki","year":"2018","unstructured":"Suzuki Y, Sakakibara M, Shiraishi N, Hirose T, Akishita M, Kuzuya M. Prescription of potentially inappropriate medications to older adults: a nationwide survey at dispensing pharmacies in Japan. Arch Gerontol Geriatr. 2018;77:8\u201312.","journal-title":"Arch Gerontol Geriatr"},{"issue":"20","key":"446_CR14","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2018.12358","volume":"320","author":"F Montastruc","year":"2018","unstructured":"Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993\u20132017. JAMA. 2018;320(20):2149\u201351.","journal-title":"JAMA"},{"issue":"10","key":"446_CR15","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1111\/jgs.17312","volume":"69","author":"SH Read","year":"2021","unstructured":"Read SH, Giannakeas V, Pop P, Bronskill SE, Herrmann N, Chen S, et al. Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain. J Am Geriatr Soc. 2021;69(10):2842\u201350.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"446_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40801-021-00244-9","volume":"8","author":"K Inada","year":"2021","unstructured":"Inada K, Enomoto M, Yamato K, Mishima K. Prescribing pattern of hypnotic medications in patients initiating treatment at Japanese hospitals: a nationwide, retrospective, longitudinal, observational study using a claims database. Drugs Real World Outcomes. 2021;8(3):277\u201388.","journal-title":"Drugs Real World Outcomes."},{"key":"446_CR17","unstructured":"Mitsubishi Tanabe Pharma Co. The interview form Depas (etizoram tablets and fine granules) [in Japanese]. 2019. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400315_1179025C1054_2_18. Accessed 6 Nov 2022."},{"key":"446_CR18","unstructured":"Viatris Inc. Lyrica\u00ae (pregabalin) [package insert]. 2023. Available from: https:\/\/www.info.pmda.go.jp\/go\/pack\/1190017F1029_3_03\/. Accessed 6 Nov 2023."},{"key":"446_CR19","unstructured":"Daiichi sankyo Co. Ltd. Tarlige\u00ae (mirogabalin) [package insert] [in Japanese]. 2023. Available from: https:\/\/www.info.pmda.go.jp\/go\/pack\/1190026F1028_1_10. Accessed 6 Nov 2023."},{"issue":"9","key":"446_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/pds.2009","volume":"19","author":"GE Caughey","year":"2010","unstructured":"Caughey GE, Roughead EE, Pratt N, Shakib S, Vitry AI, Gilbert AL. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf. 2010;19(9):977\u201382.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"446_CR21","unstructured":"Kobayashi M. Drug-induced dizziness with delayed identification of the culprit drug due to polypharmacy [in Japanese]. Yakuji [The Pharmaceuticals]. 2020; p. 1772\u20135."},{"issue":"1","key":"446_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/phar.2880","volume":"44","author":"F Shahid","year":"2024","unstructured":"Shahid F, Doherty A, Wallace E, Schmiedl S, Alexander GC, Dreischulte T. Prescribing cascades in ambulatory care: a structured synthesis of evidence. Pharmacotherapy. 2024;44(1):87\u201396.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"446_CR23","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1111\/bcp.15447","volume":"88","author":"SM Vouri","year":"2022","unstructured":"Vouri SM, Morris EJ, Wang GH, Hashim Jaber Bilal A, Hallas J, Henriksen DP. Association between gabapentinoids and oedema treated with loop diuretics: a pooled sequence symmetry analysis from the USA and Denmark. Br J Clin Pharmacol. 2022;88(12):5269\u201394.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"446_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1008","volume":"10","author":"AS Doherty","year":"2022","unstructured":"Doherty AS, Shahid F, Moriarty F, Boland F, Clyne B, Dreischulte T, et al. Prescribing cascades in community-dwelling adults: a systematic review. Pharmacol Res Perspect. 2022;10(5): e01008.","journal-title":"Pharmacol Res Perspect"},{"issue":"9","key":"446_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/pds.3440","volume":"22","author":"N Pratt","year":"2013","unstructured":"Pratt N, Andersen M, Bergman U, Choi NK, Gerhard T, Huang C, et al. Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiol Drug Saf. 2013;22(9):915\u201324.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"446_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ajh\/hpac013","volume":"35","author":"SM Vouri","year":"2022","unstructured":"Vouri SM, Morris EJ, Jiang X, Hofer AK, Schmidt S, Pepine C, et al. Evaluation of a beta-blocker-edema-loop diuretic prescribing cascade: a prescription sequence symmetry analysis. Am J Hypertens. 2022;35(7):601\u20139.","journal-title":"Am J Hypertens"},{"issue":"12","key":"446_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18425","volume":"2","author":"SM Vouri","year":"2019","unstructured":"Vouri SM, Jiang X, Manini TM, Solberg LM, Pepine C, Malone DC, et al. Magnitude of and characteristics associated with the treatment of calcium channel blocker-induced lower-extremity edema with loop diuretics. JAMA Netw Open. 2019;2(12): e1918425.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"446_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/pds.5362","volume":"31","author":"SM Vouri","year":"2022","unstructured":"Vouri SM, Morris EJ, Usmani SA, Reise R, Jiang X, Pepine CJ, et al. Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: loop diuretic prescribing cascade. Pharmacoepidemiol Drug Saf. 2022;31(1):72\u201381.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"446_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40264-020-00940-5","volume":"43","author":"CE King","year":"2020","unstructured":"King CE, Pratt NL, Craig N, Thai L, Wilson M, Nandapalan N, et al. Detecting medicine safety signals using prescription sequence symmetry analysis of a national prescribing data set. Drug Saf. 2020;43(8):787\u201395.","journal-title":"Drug Saf"},{"issue":"7","key":"446_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10654-017-0281-8","volume":"32","author":"EC Lai","year":"2017","unstructured":"Lai EC, Pratt N, Hsieh CY, Lin SJ, Pottegard A, Roughead EE, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32(7):567\u201382.","journal-title":"Eur J Epidemiol"},{"key":"446_CR31","unstructured":"Pharmaceuticals and Medical Devices Agency. Drug information search [in Japanese]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/. Accessed 6 Nov 2022."},{"issue":"9","key":"446_CR32","first-page":"1009","volume":"38","author":"K Nozawa","year":"2018","unstructured":"Nozawa K, Matui M, Yoshiyama T, Fuzii K. Safety and efficacy of pregabalin (Lyrica capsules) in patients with neuropathic pain under practical conditions [in Japanese]. Prog Med. 2018;38(9):1009\u201318.","journal-title":"Prog Med"},{"issue":"5","key":"446_CR33","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.clinthera.2021.03.015","volume":"43","author":"J Kato","year":"2021","unstructured":"Kato J, Baba M, Kuroha M, Kakehi Y, Murayama E, Wasaki Y, et al. Safety and efficacy of mirogabalin for peripheral neuropathic pain: pooled analysis of two pivotal phase III studies. Clin Ther. 2021;43(5):822-35.e16.","journal-title":"Clin Ther"},{"key":"446_CR34","unstructured":"Kaiser Permanente. Benzodiazepine and Z-drug safety guideline. 2014. Available from: https:\/\/wa.kaiserpermanente.org\/static\/pdf\/public\/guidelines\/benzo-zdrug.pdf. Accessed 6 Nov 2023."},{"issue":"6","key":"446_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.1736","volume":"18","author":"I Tsiropoulos","year":"2009","unstructured":"Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18(6):483\u201391.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"446_CR36","unstructured":"Australian Institute of Health and Welfare. Acute kidney injury in Australia: a first national snapshot. 2015. Available from: https:\/\/www.aihw.gov.au\/getmedia\/7e0f5313-d61d-4de3-ad8d-389dcc7a03dc\/19380.pdf. Accessed 5 Dec 2023."},{"key":"446_CR37","unstructured":"Japan Pharmaceutical Manufacturers Association. Real world data analysis in practice: let\u2019s try RWD analysis [in Japanese]. 2017. Available from: https:\/\/www.jpma.or.jp\/information\/evaluation\/results\/allotment\/lofurc00000083es-att\/real_world_data.pdf. Accessed 20 Dec 2022."},{"issue":"2","key":"446_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2125.2009.03571.x","volume":"69","author":"S Vegter","year":"2010","unstructured":"Vegter S, de Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect: angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010;69(2):200\u20133.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"446_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12874-017-0457-7","volume":"18","author":"Y Takeuchi","year":"2018","unstructured":"Takeuchi Y, Shinozaki T, Matsuyama Y. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. BMC Med Res Methodol. 2018;18(1):4.","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"446_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260742","volume":"16","author":"S Besharat","year":"2021","unstructured":"Besharat S, Grol-Prokopczyk H, Gao S, Feng C, Akwaa F, Gewandter JS. Peripheral edema: a common and persistent health problem for older Americans. PLoS ONE. 2021;16(12): e0260742.","journal-title":"PLoS ONE"},{"issue":"5","key":"446_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1055\/s-0030-1254105","volume":"43","author":"S Kruger","year":"2010","unstructured":"Kruger S, Lindstaedt M. Pregabalin and edema in young women suffering from premenstrual syndrome. Pharmacopsychiatry. 2010;43(5):202\u20133.","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"446_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-0028-1085443","volume":"42","author":"T Wustmann","year":"2009","unstructured":"Wustmann T, Piro J, Gutmann P. Metabolic considerations in a case of pregabalin-induced edema. Pharmacopsychiatry. 2009;42(2):75\u20136.","journal-title":"Pharmacopsychiatry"},{"issue":"9","key":"446_CR43","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","volume":"6","author":"DA Sica","year":"2004","unstructured":"Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich). 2004;6(9):532\u201340.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"446_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.3256","volume":"21","author":"SD Berry","year":"2012","unstructured":"Berry SD, Mittleman MA, Zhang Y, Solomon DH, Lipsitz LA, Mostofsky E, et al. New loop diuretic prescriptions may be an acute risk factor for falls in the nursing home. Pharmacoepidemiol Drug Saf. 2012;21(5):560\u20133.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"446_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/jgs.18103","volume":"71","author":"GH Wang","year":"2023","unstructured":"Wang GH, Morris EJ, Smith SM, Hallas J, Vouri SM. Continued potassium supplementation use following loop diuretic discontinuation in older adults: an evaluation of a prescribing cascade relic. J Am Geriatr Soc. 2023;71:505\u201315.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"446_CR46","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2337\/dc14-1044","volume":"37","author":"A Vinik","year":"2014","unstructured":"Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37(12):3253\u201361.","journal-title":"Diabetes Care"},{"issue":"3","key":"446_CR47","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the alpha(2)delta subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365(3):573\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"446_CR48","doi-asserted-by":"publisher","first-page":"204209861983603","DOI":"10.1177\/2042098619836032","volume":"10","author":"J Mendell","year":"2019","unstructured":"Mendell J, Levy-Cooperman N, Sellers E, Vince B, Kelsh D, Lee J, et al. Abuse potential of mirogabalin in recreational polydrug users. Ther Adv Drug Saf. 2019;10:2042098619836032.","journal-title":"Ther Adv Drug Saf."},{"issue":"4","key":"446_CR49","first-page":"43","volume":"28","author":"S Hagihara","year":"2021","unstructured":"Hagihara S, Nakagawa M, Kamijima K, Kuwahara S, Hayashi M, Abe Y. Assessment of clinical adverse events of mirogabalin switching from pregabalin in choronic pain management [in Japanese]. J Japan Soc Pain Clinicians. 2021;28(4):43\u20138.","journal-title":"J Japan Soc Pain Clinicians."},{"key":"446_CR50","unstructured":"Daiichi sankyo Co. Ltd. Tarlige: guideline for property use [in Japanese]. 2018. Available from: https:\/\/www.medicalcommunity.jp\/filedsp\/products$druginfo$tarlige$safety_rmp_m$TLG7RM01\/field_file_pdf. Accessed 6 Nov 2022."},{"issue":"11","key":"446_CR51","doi-asserted-by":"publisher","first-page":"e1193","DOI":"10.1212\/WNL.0000000000201709","volume":"100","author":"T Ushida","year":"2023","unstructured":"Ushida T, Katayama Y, Hiasa Y, Nishihara M, Tajima F, Katoh S, et al. Mirogabalin for central neuropathic pain after spinal cord injury. Neurology. 2023;100(11):e1193\u2013206.","journal-title":"Neurology"},{"key":"446_CR52","unstructured":"Ministry of Health, Labour and Welfare. Pharmaceuticals and medical devices safety information No. 293. 2012. Available from: https:\/\/www.pmda.go.jp\/files\/000144665.pdf#page=7. Accessed 6 Nov 2023."},{"key":"446_CR53","unstructured":"Pfizer Japan Inc. Lyrica capsule: proper use information: dizziness, somnolence, and loss of consciousness in the elderly [in Japanese]. 2012. Available from: https:\/\/www.pmda.go.jp\/files\/000144302.pdf. Accessed 6 Nov 2022."},{"key":"446_CR54","unstructured":"Daiichi sankyo Co. Ltd. Tarlige for patients receiving treatment with Tarlige [in Japanese]. 2018. Available from: https:\/\/www.medicalcommunity.jp\/filedsp\/products$druginfo$tarlige$safety_rmp_p$TLG1P001\/field_file_pdf. Accessed 6 Nov 2022."},{"issue":"3","key":"446_CR55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.pharmthera.2005.09.007","volume":"110","author":"L Veenman","year":"2006","unstructured":"Veenman L, Gavish M. The peripheral-type benzodiazepine receptor and the cardiovascular system: implications for drug development. Pharmacol Ther. 2006;110(3):503\u20134.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"446_CR56","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0002-9343(02)01322-0","volume":"113","author":"S Cho","year":"2002","unstructured":"Cho S, Atwood JE. Peripheral edema. Am J Med. 2002;113(7):580\u20136.","journal-title":"Am J Med"},{"key":"446_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173744","volume":"892","author":"S Kagota","year":"2021","unstructured":"Kagota S, Morikawa K, Ishida H, Chimoto J, Maruyama-Fumoto K, Yamada S, et al. Vasorelaxant effects of benzodiazepines, non-benzodiazepine sedative-hypnotics, and tandospirone on isolated rat arteries. Eur J Pharmacol. 2021;892: 173744.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"446_CR58","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jsps.2018.07.010","volume":"26","author":"AF Badr","year":"2018","unstructured":"Badr AF, Kurdi S, Alshehri S, McManus C, Lee J. Pharmacists\u2019 interventions to reduce sedative\/hypnotic use for insomnia in hospitalized patients. Saudi Pharm J. 2018;26(8):1204\u20137.","journal-title":"Saudi Pharm J."},{"issue":"2","key":"446_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1477-7525-2-17","volume":"24","author":"L Frighetto","year":"2004","unstructured":"Frighetto L, Marra C, Bandali S, Wilbur K, Naumann T, Jewesson P. An assessment of quality of sleep and the use of drugs with sedating properties in hospitalized adult patients. Health Qual Life Outcomes. 2004;24(2):17.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"446_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3757\/jser.78.7","volume":"78","author":"N Yasuyuki","year":"2019","unstructured":"Yasuyuki N. Recently introduced anti-dizziness\/vertigo drugs in Japan [in Japanese]. Equil Res. 2019;78(1):7\u201315.","journal-title":"Equil Res"},{"key":"446_CR61","unstructured":"National Institute for Health and Care Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. 2004 . Available from: https:\/\/www.nice.org.uk\/guidance\/ta77\/informationforpublic. Accessed 6 Nov 2022."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-024-00446-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-024-00446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T03:34:04Z","timestamp":1725161644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-024-00446-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40801-024-00446-x","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"2 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hisashi Urushihara has received research funds from Daiichi Sankyo Co. Ltd., outside of the present work and bearing no role in it. Rina Omata, Akane Asami, and Azusa Hara have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study protocol was approved by the Ethics Committee for Research Involving Humans of Keio University Faculty of Pharmacy (No. 220406-2), according to the local ethical guidelines for biological and medical research involving human subjects. This study was conducted for non-commercial purposes by an academic research organization, and the requirement for individual consent to the collection and secondary use of existing personal health data was therefore waived according to the Japanese Privacy Protection Law.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this published article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization, RO and HU; methodology, RO and HU; formal analysis, RO and HU; validation, AA; resources, HU; writing - original draft preparation; RO; writing - review and editing; AA, AH, and HU; supervision, AH and HU. All authors gave final approval of the version to be published, and agreed on the journal to which the article has been submitted. Further, all authors agree to take responsibility and be accountable for the contents of the article. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}